Tripokin is a fully-human immunostimulatory product consisting of a human vascular targeting antibody, simultaneously fused to both human interleukin 2 (IL2) and human tumor necrosis factor alpha (TNFa). IL2 is a cytokine that stimulates immune effector cells, while TNF is a strong pro-inflammatory cytokine.
Considering that TNF is more potent than IL2, a single point mutation in the TNF moiety was introduced to match the biological activity of the two cytokines. The rationale for the development of this product relies on the fact that the combination of IL2- and TNF- based immunocytokines showed a strong synergistic effect in both pre-clinical and clinical studies.
De Luca et al. (2017) Mol Cancer Ther, 16(11); 2442–51;
Danielli et al. (2015) Cancer Immunol. Immunother. 64, 999-1009;
Hemmerle and Neri (2013) Br. J. Cancer 109 (5) 1206-13;
Schwager et al. (2013) J. Invest. Dermatol., 133, 751-8;
Papadia et al. (2013) J Surg Oncol., 107, 173-179;
Eigentler et al. (2011) Clin. Cancer Res., 17, 7732-42;
Balza et al. (2006) Clin. Cancer Res., 12, 2575-2582;
Borsi et al. (2003) Blood, 102, 4384-4392.